2,3-Dihydro-6,7-dimethyl-1,4-benzodioxin | 4685-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2,3-Dihydro-6,7-dimethyl-1,4-benzodioxin
• 英文别名: 6,7-dimethyl-2,3-dihydro-1,4-benzodioxine
• CAS: 4685-49-8
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.2
• InChiKey: BUMCDRCOCLJFKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-Dihydro-6,7-dimethyl-1,4-benzodioxin 、 溴 以78%的产率得到
  参考文献：
  名称：

  DALLACKER F.; REICHRATH G.; SCHNACKERS G., Z. NATURFORSCH., 1979, B 34, NO 4, 624-632

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二甲基苯-1,2-二醇 、 1,2-二溴乙烷 以39%的产率得到
  参考文献：
  名称：

  DALLACKER F.; REICHRATH G.; SCHNACKERS G., Z. NATURFORSCH., 1979, B 34, NO 4, 624-632

  摘要：

  DOI：

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243527A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• [EN] SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRROLO[1,2-Α]TRIAZINES SUBSTITUÉES ET COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017192929A1

  公开（公告）日：2017-11-09

  The invention provides substituted pyrrolo[1,2-α]triazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]triazines compounds described herein include substituted 2,4-dimethyl-pyrrolo[1,2-α] [1,3,5]triazine-8-carboxamide compounds and variants thereof.

  该发明提供了替代吡咯并[1,2-α]三唑化合物，相关化合物，含有这些化合物的组合物，医疗用品包，以及使用这些化合物和组合物来治疗医学疾病的方法，例如高雪氏病、帕金森病、Lewy小体病、痴呆症或多系统萎缩症等。本文描述的示例替代吡咯并[1,2-a]三唑化合物包括替代的2,4-二甲基-吡咯并[1,2-α][1,3,5]三唑-8-羧酰胺化合物及其变体。
• [EN] THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY<br/>[FR] THIAZOLO(3,2-A)PYRIMIDINONE ET AUTRES COMPOSÉS HÉTÉROBICYCLIQUES DE PYRIMIDINONE POUR UTILISATION À DES FINS THÉRAPEUTIQUES
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017040879A1

  公开（公告）日：2017-03-09

  The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo- 2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxarnide compounds.

  该发明提供了异双环嘧啶酮化合物，例如噻唑并[3,2-a]嘧啶酮化合物，含有这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗医学疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症。本文描述的示例异双环嘧啶酮化合物包括5-氧代-2,3-二氢-5H-噻唑并[3,2-a]嘧啶-6-羧酰胺化合物。
• [EN] HETEROBICYCLIC PYRIMIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES DE PYRIMIDINONE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017040877A1

  公开（公告）日：2017-03-09

  The invention provides heterobicyclic pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 6-oxo-3,4-dihydro-2H,6H-pyrimido[2,1-b)][1,3]thiazine-7-carboxamide compounds.

  该发明提供了杂环嘧啶酮化合物，包含这样的化合物的组合物，医疗工具箱，以及使用这样的化合物和组合物治疗患者的医疗紊乱的方法，例如高氏病，帕金森病，Lewy体病，痴呆症，或多系统萎缩。这里描述的示例杂环嘧啶酮化合物包括6-氧-3,4-二氢-2H,6H-嘧啶并[2,1-b][1,3]噻嗪-7-羧酰胺化合物。
• Trisubstituted amine compound
  申请人：Nakamura Yoshinori

  公开号：US20090029994A1

  公开（公告）日：2009-01-29

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R 1 is an optionally substituted alkyl group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一般式(1)的化合物，其中Y是亚甲基基团等；A是可选择取代的杂环基团等；B是可选择取代的苯基团等；R1是可选择取代的烷基团等；R2是可选择取代的氨基团等；或其药学上可接受的衍生物，该化合物具有胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于动脉粥样硬化疾病、高脂血症或异常脂质血症的预防和/或治疗等。